Back to Trials
NCT05945121NARecruiting

Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

University of Michigan Rogel Cancer Center

Start Date

8/25/2023

Completion Date

8/1/2027

Summary

To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Adult 18 years or older * Referred for HSCT evaluation * Presence of least one CV risk factor at enrollment (hypertension, hyperlipidemia, atrial fibrillation, obesity, heart failure, history of coronary artery disease, diabetes) * Able to ambulate unassisted * Ability to understand and the willingness to sign a written informed consent * Ability to use Polar Flow heart rate application Exclusion Criteria: * Severe anemia (hemoglobin \<7 gm/dl) * Untreated high-risk coronary artery disease (left main, triple vessel disease) * Severe aortic stenosis * Recent fracture as assessed via self-report * Gross balance deficits * Severe pain with basic movement * Unable to ambulate unassisted or exercise * NYHA class IV heart failure * Adults unable to give consent, pregnant women, and prisoners are excluded from this study.

Interventions

OTHER

Cardio-oncology program

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Hematopoietic Stem Cell Transplant

Locations

University of Michigan Rogel Cancer Center

Ann Arbor, Michigan 48109

United States